Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash from Operations (2016 - 2025)

Spyre Therapeutics' Cash from Operations history spans 11 years, with the latest figure at 44578000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 19.84% year-over-year to 44578000.0; the TTM value through Dec 2025 reached 169252000.0, down 7.52%, while the annual FY2025 figure was 169252000.0, 7.52% down from the prior year.
  • Cash from Operations reached 44578000.0 in Q4 2025 per SYRE's latest filing, down from 37117000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 2082000.0 in Q2 2021 to a low of 62248000.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 28021600.0, with a median of 27402500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: surged 110.72% in 2021, then crashed 1092.94% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 19268000.0 in 2021, then grew by 5.85% to 18140000.0 in 2022, then plummeted by 71.09% to 31036000.0 in 2023, then dropped by 19.86% to 37199000.0 in 2024, then fell by 19.84% to 44578000.0 in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Cash from Operations are 44578000.0 (Q4 2025), 37117000.0 (Q3 2025), and 46563000.0 (Q2 2025).